ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Ticker
$ATAI
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
54
ISIN
NL0015000DX5
Website
ATAI Metrics
BasicAdvanced
$468M
-
-$0.91
1.22
-
Price and volume
Market cap
$468M
Beta
1.22
52-week high
$2.64
52-week low
$1.03
Average daily volume
2.6M
Financial strength
Current ratio
4.069
Quick ratio
3.446
Long term debt to equity
9.317
Total debt to equity
19.351
Interest coverage (TTM)
-23.60%
Profitability
EBITDA (TTM)
-94.351
Gross margin (TTM)
-481.75%
Net profit margin (TTM)
-7,997.16%
Operating margin (TTM)
-5,198.98%
Effective tax rate (TTM)
0.50%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-26.04%
Return on equity (TTM)
-79.43%
Valuation
Price to revenue (TTM)
205.758
Price to book
3.06
Price to tangible book (TTM)
3.13
Price to free cash flow (TTM)
-4.863
Free cash flow yield (TTM)
-20.56%
Free cash flow per share (TTM)
-47.91%
Growth
Revenue change (TTM)
572.56%
Earnings per share change (TTM)
327.65%
3-year revenue growth (CAGR)
55.45%
3-year earnings per share growth (CAGR)
-13.49%
What the Analysts think about ATAI
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
Bulls say / Bears say
Maxim Group upgraded ATAI Life Sciences' stock, citing its strategic investment in Beckley Psytech, which focuses on developing short-duration psychedelics. (seekingalpha.com)
ATAI Life Sciences announced positive results from its Phase 2a study of BPL-003, a treatment for moderate to severe alcohol use disorder, showing significant improvements in alcohol consumption and heavy drinking days. (stockstotrade.com)
The company appointed Dr. Srinivas Rao as CEO and Gerd Kochendoerfer as COO, signaling a strategic realignment aimed at advancing novel treatments for mental health disorders. (stockstotrade.com)
ATAI Life Sciences' stock experienced a significant drop of 5.52%, trading at $1.54, amidst market volatility and a net loss of $26.29 million in the recent financial report. (gurufocus.com)
The company announced a $55 million common stock offering, which led to a decline in share price due to potential dilution concerns among investors. (nasdaq.com)
ATAI Life Sciences reported a net loss of $26.29 million and an earnings per share of -$0.16, reflecting ongoing financial challenges. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ATAI Financial Performance
Revenues and expenses
ATAI Earnings Performance
Company profitability
ATAI News
AllArticlesVideos
Psychedelics regain momentum in 2025 on political tailwinds, clinical wins
Proactive Investors·19 hours ago
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks
Proactive Investors·2 days ago
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Atai Life Sciences N.V.
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $468M as of June 20, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of June 20, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.